Baidu
map

中医药领军人才支持计划将实施

2018-06-13 李琳 健康报

近日,国家中医药管理局印发《中医药传承与创新“百千万”人才工程(岐黄工程)——国家中医药领军人才支持计划》,计划遴选100名岐黄学者和10名中医药首席科学家。遴选工作由国家中医药管理局负责。

近日,国家中医药管理局印发《中医药传承与创新“百千万”人才工程(岐黄工程)——国家中医药领军人才支持计划》,计划遴选100名岐黄学者和10名中医药首席科学家。遴选工作由国家中医药管理局负责。

《计划》要求,岐黄学者应在中医药临床实践或中医药基础理论研究、应用研究中取得重大成果,所从事的工作取得突出成绩,在国内外具有较高学术影响力的专业技术人员,分临床型和科研型。

《计划》强调,岐黄学者应结合所从事研究领域,围绕中医药发展需求和重点问题,开展创新性、探索性和应用性研究,加强团队建设,积极推动解决中医药领域发展中面临的临床或科研难题,形成行业内外有较大影响力的标志性成果,中医药研究和服务能力明显提升,成为中医药领军人才。中医药首席科学家应结合所从事研究领域,聚焦中医药重点发展需求和重大科学问题,开展原创性、探索性研究,建设创新团队,形成国内外有较大影响力的标志性成果,在本领域内产生较大经济效益或社会效益,成为中医药战略型领军人才。中央财政为岐黄学者、中医药首席科学家分别安排人均不高于60万元、100万元的经费支持,用于自主选题研究、学习交流、人才培养和团队建设等。

据悉,该《计划》实施周期为期3年。考核评价采取中期考核、终期评价的方式进行。省级中医药主管部门负责中期考核,并将考核结果报国家中医药管理局。国家中医药管理局第3年组织终期评价。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820286, encodeId=15211820286d1, content=<a href='/topic/show?id=b1451004935a' target=_blank style='color:#2F92EE;'>#领军人才支持计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100493, encryptionId=b1451004935a, topicName=领军人才支持计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Fri Jul 13 08:30:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409576, encodeId=693214095e655, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jun 15 08:30:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323914, encodeId=64e132391463, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Jun 13 20:05:00 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820286, encodeId=15211820286d1, content=<a href='/topic/show?id=b1451004935a' target=_blank style='color:#2F92EE;'>#领军人才支持计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100493, encryptionId=b1451004935a, topicName=领军人才支持计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Fri Jul 13 08:30:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409576, encodeId=693214095e655, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jun 15 08:30:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323914, encodeId=64e132391463, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Jun 13 20:05:00 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
    2018-06-15 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820286, encodeId=15211820286d1, content=<a href='/topic/show?id=b1451004935a' target=_blank style='color:#2F92EE;'>#领军人才支持计划#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100493, encryptionId=b1451004935a, topicName=领军人才支持计划)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=21e5394, createdName=yeaweam, createdTime=Fri Jul 13 08:30:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409576, encodeId=693214095e655, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jun 15 08:30:00 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323914, encodeId=64e132391463, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Wed Jun 13 20:05:00 CST 2018, time=2018-06-13, status=1, ipAttribution=)]
    2018-06-13 phoebeyan520

    谢谢分享.学习了

    0

Baidu
map
Baidu
map
Baidu
map